4. Teva Pharmaceutical is an Israel-based maker of generic drugs, specialty pharmaceuticals and pharmaceutical ingredients. It's the largest generic drug maker in the world. Net revenue reported for the second quarter was $4.2 billion, up 11% from the corresponding period in 2010. The Gross profit margin during fourth quarter of 2010 was a healthy 57.3%. The company's cash flow from operations stood at $1.3 billion, along with free cash flow of $897 million. Teva's performance during the second quarter saw increased contributions from its European business. It also saw double-digit growth in markets like Latin America and Asia. Strong growth was observed in several branded franchises like women's health. Another positive is the settlement of patent litigation in relation to the launch of generic Lotrel and generic Neurontin. Revenue guidance for fiscal 2011 stood at $18.5 billion to $19 billion, with EPS ranging from $4.90 to $5.20. On average, analysts expect the stock to gain 63% over the next year. Seventy-nine percent of analysts rate the stock a buy. Shares are trading at a P/E of 7 based on estimated 2011 earnings.